Loading…
Loading…
Genscript Biotech Corporation (GNNSF) Q4 2025 Earnings Call Transcript
Group Performance Revenue: US$959.5 million, +61.4% year-on-year Gross profit: US$553.2 million, +103.3% year-on-year Adjusted net profit: US$230.3 million, +285.0% year-on-year Business Units' Performance GenScript Life Science Group (LSG): US$522.1 million, +14.8% year-on-year ProBio: US$388.7 million, +309.1% year-on-year Bestzyme: US$58.0 million, +7.9% year-on-year PISCATAWAY, N.J., March 16, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology innovation, today announced financial results for full year 2025.
Genscript Biotech Corporation (OTCPK:GNNSF) Q2 2025 Earnings Conference Call August 17, 2025 7:00 PM ET Company Participants Aixi Bai - General Manager of Bestzyme Allen Guo - CEO of ProBio Josie Zhou - Interim CFO Ray Chen - President of GenScript Life Science Group Weihui Shao - CEO & COO Conference Call Participants Daisy Cheng - Morgan Stanley, Research Division Wai Chak Yuen - Daiwa Securities Co. Ltd., Research Division Wanhua Wu - China International Capital Corporation Limited, Research Division Yang Huang - JPMorgan Chase & Co, Research Division Good day and thank you for standing by.
Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation PISCATAWAY, N.J. , Aug. 17, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global pioneer in life sciences innovation, today announced outstanding interim results for the first half of 2025, underscoring its ability to deliver profitable growth at scale through strategic globalization, differentiated technology, and relentless innovation.
PISCATAWAY, N.J. , July 31, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that its ESG rating has been upgraded to AA from A by MSCI in recognition of the company's excellence in the areas of product safety & quality and human capital development, as well as continuous improvement in environment and governance practices.
Strategic deconsolidation of Legend Biotech unlocked significant value, while core businesses experienced rapid growth. PISCATAWAY, N.J.
LONDON , Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech Global Forum in London, UK. Since its inaugural session at the J.P.
PISCATAWAY, N.J. , Nov. 10, 2024 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript"), a global leader in life sciences services and products, has announced the establishment of new operations site and logistics center in Sydney, Australia.
No recent filings indexed.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for GNNSF and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.